PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Ian W. Flinn, MD, PhD - Innovative Therapy for B-Cell Malignancies: A MasterClass and Tumor Board on Decision-Making in CLL, FL, and MCL
Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView’s latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies